Key Publications

Fei F, Lim M, George A, Kirzner J, Lee D, Seeger R, Groffen J, *Abdel-Azim H, *Heisterkamp N. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. Leukemia, 29, 788-797, 2015.
 
Fei F, Joo EJ, Tarighat SS, Schiffer I, Paz H, Fabbri M, Abdel-Azim H, Groffen J, Heisterkamp N. B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.  Oncotarget, 6, 11378-11394, 2015.
 
Parameswaran R, Lim M, Fei F, Abdel-Azim H, Arutyunyan A, Schiffer I, McLaughlin ME, Gram H, Huet H, Groffen J, Heisterkamp N. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc engineered monoclonal antibody targeting the BAFF-R. Mol. Cancer Ther. 13, 1567-1577, 2014.
 
Oncoimmunology 1:618-629, 2012.Fei F, Abdel-Azim, H, Lim M, Arutyunyan A, von Itzstein M, Groffen J, Heisterkamp N. Galectin-3 in pre-B acute lymphoblastic leukemia. Leukemia 27: 2385-2388, 2013.
 
Parameswaran R, Yu M, Lim M, Lyu M-A, Rosenblum, MG, Groffen J, Heisterkamp N. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin. Leukemia 26:1786-1796, 2012.
 
Yu M, Jiang E, Parameswaran R, Stoddart S, Fei F, Muschen M, Park E, Hsieh Y-T, Martinelli G, Hofmann W-K, Yang AS, Groffen J, Heisterkamp N, Kim Y-m. AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo. Blood Cancer J. 1:e14, 2011. 
 
Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 25:1314-1323, 2011.
https://www.nature.com/leu/journal/v25/n8/full/leu201176a.html
 
Feldhahn N, Arutyunyan A, Stoddart S, Zhang B, Schmidhuber SM, Yi S-J, Kim Y-m, Groffen J, Heisterkamp N. Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. http://www.tandfonline.com/doi/full/10.4161/onci.20249